Afamitresgene autoleucel as an effective T-cell therapy for synovial sarcoma and liposarcoma
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature ...
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature ...
1. 71% patients achieved complete remission or complete remission with incomplete recovery following KTE-X19 infusion. 2. The majority of adverse ...
Genetically engineered T-cell therapies, such as chimeric antigen receptor T-cells (CAR T-cells), have been approved for the treatment of hematologic ...
Pregnancy duration and endometrial cancer risk: nationwide cohort study Full-term pregnancies are strongly associated with a reduced risk of endometrial ...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve ...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.